DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the NASH Pipeline @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight
Key Takeaways from the NASH Pipeline Report
- On May 22, 2026- GlaxoSmithKline initiated a study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
- On May 20, 2026- Inventiva Pharma conducted a Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts – an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives.
- On May 18, 2026- Akero Therapeutics Inc. announced a phase 3 Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH.
- On May 18, 2026- Altimmune Inc. announced a phase 2 study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
- On May 13, 2026- Madrigal Pharmaceuticals Inc. initiated a Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease.
- On May 08, 2026- Corcept Therapeutics initiated a phase 2b study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant twice a week for 6 weeks of treatment, followed by a dose escalation to 200 mg miricorilant or placebo twice weekly for an additional 18 weeks which resulting in a total treatment duration of 24 weeks, or to placebo for 24 weeks. (Cohort B).
- DelveInsight’s NASH Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for NASH treatment.
- The leading NASH Companies such as Novo Nordisk, Haisco Pharmaceutical Group Co., Ltd., Viking Therapeutics, Tasly Biopharmaceuticals Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Sunshine Lake Pharma Co., Ltd, Corcept Therapeutics, J2H Biotech, GlaxoSmithKline, Hinova Pharmaceuticals Inc., Rivus Pharmaceuticals, Inc., Viking Therapeutics, Inc., Sinew Pharma Inc., Guangdong Raynovent Biotech Co., Ltd, Aligos Therapeutics, Inventiva Pharma, HighTide Biopharma Pty Ltd, MediciNova, Hudson Biotech, OrsoBio, Inc., 89bio, Inc., Inipharm Australia Pty Ltd, Changchun Intellicrown Pharmaceutical Co. LTD, Sino Biopharmaceutical Limited, NorthSea Therapeutics B.V. and others.
- Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.
Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs
Non-Alcoholic Steatohepatitis Overview
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), characterized by the presence of liver inflammation and hepatocyte injury (ballooning) due to fat accumulation. There are four different clinical phases described for NAFLD. Phase 1 is characterized by simple steatosis and is considered harmless. Some patients progress to Phase 2 developing inflammation and ballooning (NASH). Phase 3 is defined by the presence of NASH with persistent inflammation resulting in liver fibrosis (scarring), which is considered the strongest predictor of liver-related events in NASH patients. Over time, this 3rd stage can lead to a more serious condition, such as liver cirrhosis (Phase 4) or even cancer, where a liver transplant is the only therapy option.
NASH Emerging Drugs Profile
- Efruxifermin: Novo Nordisk
Efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX appears to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipid metabolism. This holistic approach offers the potential to address the complex, multi-system disease state of MASH, including improvements in lipoprotein risk factors linked to cardiovascular disease the leading cause of death in MASH patients. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).
- HSK-31679: Haisco Pharmaceutical Group Co., Ltd.
HSK31679 is a novel, liver-directed, orally active thyroid hormone receptor-beta agonist designed to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) and liver fibrosis. It shows superior preclinical efficacy in reducing liver fat and inflammation compared to MGL-3196 (Resmetirom) by modulating gut microbial sphingolipids and inducing an anti-inflammatory environment. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).
- VK2809: Viking Therapeutics
VK2809, is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promise for the treatment of metabolic disorders, including non-alcoholic steatohepatitis (NASH). The compound successfully achieved both the primary and secondary endpoints in a Phase IIb study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.
- B1344: Tasly Biopharmaceuticals Co., Ltd.
B1344 is a novel, long-acting polyethylene glycolylated (PEGylated) fibroblast growth factor 21 (FGF21) analog developed for treating nonalcoholic steatohepatitis (NASH) and metabolic diseases. B1344 is sufficient to selectively activate signaling from the βKlotho/FGFR1c receptor complex. In cynomolgus monkeys with nonalcoholic fatty liver disease (NAFLD), administration of B1344 via subcutaneous injection for 11 weeks caused a profound reduction of hepatic steatosis, inflammation, and fibrosis, along with amelioration of liver injury and hepatocyte death, as evidenced by liver biopsy specimen and biochemical analysis. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).
- ACT500: Xiamen Amoytop Biotech Co., Ltd.
ACT500 (formerly known as NM6606) is an investigational drug candidate being developed by Xiamen Amoytop Biotech Co., Ltd. (Amoytop Biotech), undergoing early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetics (PK) for treating metabolic liver diseases. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Non-Alcoholic Steatohepatitis (NASH).
The NASH Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment.
- NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market
Explore groundbreaking therapies and clinical trials in the NASH Pipeline @ New NASH Treatment Drugs
NASH Companies
Novo Nordisk, Haisco Pharmaceutical Group Co., Ltd., Viking Therapeutics, Tasly Biopharmaceuticals Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Sunshine Lake Pharma Co., Ltd, Corcept Therapeutics, J2H Biotech, GlaxoSmithKline, Hinova Pharmaceuticals Inc., Rivus Pharmaceuticals, Inc., Viking Therapeutics, Inc., Sinew Pharma Inc., Guangdong Raynovent Biotech Co., Ltd, Aligos Therapeutics, Inventiva Pharma, HighTide Biopharma Pty Ltd, MediciNova, Hudson Biotech, OrsoBio, Inc., 89bio, Inc., Inipharm Australia Pty Ltd, Changchun Intellicrown Pharmaceutical Co. LTD, Sino Biopharmaceutical Limited, NorthSea Therapeutics B.V. and others.
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
NASH Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight’s expert analysis @ NASH Market Drivers and Barriers
Scope of the NASH Pipeline Report
- Coverage- Global
- NASH Companies- Novo Nordisk, Haisco Pharmaceutical Group Co., Ltd., Viking Therapeutics, Tasly Biopharmaceuticals Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Sunshine Lake Pharma Co., Ltd, Corcept Therapeutics, J2H Biotech, GlaxoSmithKline, Hinova Pharmaceuticals Inc., Rivus Pharmaceuticals, Inc., Viking Therapeutics, Inc., Sinew Pharma Inc., Guangdong Raynovent Biotech Co., Ltd, Aligos Therapeutics, Inventiva Pharma, HighTide Biopharma Pty Ltd, MediciNova, Hudson Biotech, OrsoBio, Inc., 89bio, Inc., Inipharm Australia Pty Ltd, Changchun Intellicrown Pharmaceutical Co. LTD, Sino Biopharmaceutical Limited, NorthSea Therapeutics B.V. and others.
- NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036, and others.
- NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on NASH Pipeline Therapies and clinical trials @ NASH Companies, Key Products and Unmet Needsa
Table of Contents
- Introduction
- Executive Summary
- Nonalcoholic Steatohepatitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Lanifibranor: Inventiva Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TERN-501: Terns Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- LY3849891: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Nonalcoholic Steatohepatitis Key Companies
- Nonalcoholic Steatohepatitis Key Products
- Nonalcoholic Steatohepatitis- Unmet Needs
- Nonalcoholic Steatohepatitis- Market Drivers and Barriers
- Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
- Nonalcoholic Steatohepatitis Analyst Views
- Nonalcoholic Steatohepatitis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight